Conversely, high-grade immune-related adverse events (irAEs), such as hepatitis, pneumonitis, thyroiditis, dermatitis, and colitis were linked to both CTLA-4 inhibition and PD-1/PD-L1 blocking [184–186]. The gene discussed is CTLA4; the disease is Hepatitis.